OVERVIEW

Our Board consists of nine Directors, comprising three executive Directors, three non-executive Directors and three independent non-executive Directors. All Directors are elected by the general meeting for a term of three years which is renewable upon re-election. The major powers and functions of the Board include, but are not limited to, convening the general meetings, presenting reports to the general meetings, implementing the resolutions passed at the general meetings, determining the operational plans and investment plans of the Group, determining the fundamental management systems of the Group, formulating profit distribution plans and loss recovery plans of the Group, and exercising other powers and functions as conferred by the Articles of Association.

Our senior management is responsible for the management of day-to-day operations of the Group.

DIRECTORS AND SENIOR MANAGEMENT

The following table sets forth certain information of our Directors:

Name	Age	Position	Principal roles and responsibilities	Date of joining our Group	Date of appointment as Director	Relationship with other Directors and senior management
Ms. GENG Jie . . .	39	Chairwoman of the Board and executive Director	Responsible for overall development strategies, major decisions and overall management of the Group	July 1, 2019	July 17, 2019	Spouse of Mr. XUE Yuan; sister of Mr. GENG Yuefei
Mr. SU Yazhou (蘇亞洲)	40	Executive Director and chief executive officer	Responsible for the overall operations and management and participating in formulating material plans of the Company	December 5, 2019	March 6, 2023	None
Mr. XUE Yuan (薛源).	43	Executive Director and chief technology officer	Responsible for overseeing information technology and supply chain operations and participating in formulating material plans of the Company	December 1, 2019	October 31, 2023	Spouse of Ms. GENG Jie
Mr. GENG Yuefei (耿越飛)	46	Non-executive Director	Responsible for reviewing material plans and development strategies of the Company	October 31, 2023	October 31, 2023	Brother of Ms. GENG Jie
Dr. David Guowei WANG	64	Non-executive Director	Responsible for reviewing material plans and development strategies of the Company	May 25, 2020	May 25, 2020	None
Mr. HU Huanrui (胡煥瑞)	57	Non-executive Director	Responsible for reviewing material plans and development strategies of the Company	September 22, 2025	September 22, 2025	None

Name	Age	Position	Principal roles and responsibilities	Date of joining our Group	Date of appointment as Director	Relationship with other Directors and senior management
Dr. SUN Xiaobo (孫曉波)	67	Independent non-executive Director	Responsible for providing independent opinion and judgment to the Board	[●]	[●]	None
Mr. LAU King Pak (劉勁柏)	54	Independent non-executive Director	Responsible for providing independent opinion and judgment to the Board	[●]	[●]	None
Mr. CAI Longjun (蔡龍軍)	42	Independent non-executive Director	Responsible for providing independent opinion and judgment to the Board	[●]	[●]	None

DIRECTORS

Executive Directors

Ms. GENG Jie, aged 39, is Chairwoman of the Board and our executive Director. Ms. Geng served as chairwoman of the Board since July 2019.

Prior to joining the Group, Ms. Geng served as a product procurement manager in Sichuan Medical Trade from July 2009 to June 2012. She then served in Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司) (formerly known as Sichuan Good Doctor Pharmaceutical Group Co., Ltd. (四川好醫生藥業集團有限公司) from January 2010 to September 2018, and Sichuan Good Doctor Pharmaceutical Co., Ltd (四川好醫生製藥有限公司) before January 2010), consecutively as (i) an assistant to the chairperson of the board of directors from July 2012 to September 2016, (ii) an executive deputy general manager from October 2016 to December 2018, and (iii) an assistant to the chairperson of the board and deputy general manager of finance of the group (集團財務副總) from January 2019 to November 2019.

Ms. Geng obtained her bachelor's degree of mathematics from University of Waterloo in Canada in June 2009.

Mr. SU Yazhou (蘇亞洲), aged 40, is our executive Director and chief executive officer. Mr. Su has joined the Group and served as the general manager of the private-label pharmaceutical business division from December 2019 to October 2022. He has served as the chief executive officer of the Company since October 2022 and our Director since March 2023.

Prior to joining our Group, Mr. Su served in Good Doctor Pharmaceutical Group Co., Ltd., consecutively as (i) a district manager (片區經理) from February 2008 to December 2010, (ii) a regional director (大區總監) from December 2010 to December 2014, (iii) the general manager of the first business division (第一事業部總經理) from December 2014 to December 2016, (iv) a deputy general manager of the marketing center from January 2017 to December 2019, and (v) the general manager of the marketing center and a deputy general manager of the group from January 2020 to October 2022.

Mr. Su obtained his bachelor's degree of management majoring in marketing from Southwest University of Science and Technology (西南科技大學) in Sichuan Province, the PRC in June 2008. He is currently enrolled in the master of business administration (iMBA) program jointly organized by University of Electronic Science and Technology of China and Webster University (電子科技大學–美國韋伯斯特大學合作舉辦工商管理碩士(iMBA)項目) to pursue his master's degree.

Mr. XUE Yuan (薛源), aged 43, is our executive Director and chief technology officer. Mr. Xue has joined the Group and served as a deputy general manager of our Company since December 2019, and has served as our Director since October 2023.

Prior to joining our Group, Mr. Xue served as the chief information officer at Good Doctor Pharmaceutical Group Co., Ltd. from December 2006 to November 2019.

Mr. Xue obtained his bachelor's degree majoring in e-commerce from Beijing University of Posts and Telecommunications (北京郵電大學) in Beijing, the PRC in July 2005, and his master's degree of arts majoring in communication from Hong Kong Baptist University (香港浸會大學) in Hong Kong in November 2006.

Non-executive Directors

Mr. GENG Yuefei (耿越飛), aged 46, is a non-executive Director of our Company. Mr. Geng has joined the Group and served as our Director since October 2023 and was re-designated as our non-executive Director in September 2025.

Prior to joining our Group, Mr. Geng served as the general manager of Sichuan Medical Trade from January 2004 to July 2015. Then he has served in Good Doctor Pharmaceutical Group Co., Ltd. since August 2015, consecutively as the general manager of the marketing center from August 2015 to November 2021 and the general manager of the group since November 2021. Simultaneously, Mr. Geng has held numerous social positions, including (i) vice president of Liangshan Federation of Industry and Commerce (涼山州工商業聯合會), (ii) a representative of Xichang City 11th People's Congress, (iii) a deputy director of Good Doctor National Enterprise Technology Center (好醫生國家級企業技術中心), (iv) a deputy director of Sichuan Key Laboratory of Pharmaceutical American Cockroach (藥用美洲大蠊四川省重點實驗室), and (v) a deputy director of Sichuan Pharmaceutical Animal Engineering Technology Research Center (四川省藥用動物工程技術研究中心).

Mr. Geng is currently pursuing his associate degree in business administration at The Open University of China (國家開放大學) in Beijing, the PRC.

Since 2014, Mr. Geng has been recognized for his contributions through various awards, including (i) being recognized as Liangshan Prefecture's 13th Batch of Outstanding Contribution Elite Talents (涼山州第十三批有突出貢獻拔尖人才) by the CPC Liangshan Prefecture Committee (中共涼山州委) and the People's Government of Liangshan Prefecture (涼山州人民政府) in July 2014, (ii) being recognized as Xichang City's Outstanding Innovation and Entrepreneurship Talent (西昌市優秀創新創業人才) by the CPC Xichang Municipal Committee (中共西昌市委) and the People's Government of Xichang City (西昌市人民政府) in January 2019, (iii) being awarded the Poverty Alleviation Campaign Individual Advanced Award of the China Democratic National Construction Association (民建脱貧攻堅獎先進個人) by the Central Committee of the China Democratic National Construction Association (中國民主建國會中央委員會) in December 2019, (iv) being recognized as a leading entrepreneur in Liangshan's "Elite Plan" (涼山州"菁英計劃"涼山創業領軍人才) by the Organization Department of CPC Liangshan Prefecture Committee (中共涼山州委組織部), the

Science and Technology Bureau of Liangshan Prefecture (涼山州科學技術局), and the Human Resources and Social Security Bureau of Liangshan Prefecture (涼山州人力資源和社會保障局) in December 2021, (v) being awarded the Second Prize of Sichuan Provincial Science and Technology Progress Award (四川省科學技術進步獎二等獎) by the People's Government of Sichuan Province (四川省人民政府) twice, in March 2022 and March 2023 respectively, (vi) being named an Outstanding Individual in Xichang City's Talent Work during the 13th Five-Year Plan (十三五期間西昌市人才工作先進個人) by the Office of the CPC Xichang Municipal Committee (中共西昌市委辦公室) and the Office of the People's Government of Xichang City (西昌市人民政府辦公室) in November 2022, (vii) being recognized as one of the top ten outstanding contribution entrepreneurs (十大突出貢獻企業家) by the CPC Xichang Municipal Committee and the People's Government of Xichang City in March 2023, (viii) being recognized as an Outstanding Talent of Xichang City (西昌市傑出人才) by the People's Government of Xichang City in December 2023, and (ix) being designated a national model worker in the industrial and information technology field (全國工業和信息化系統勞動模範) by the Ministry of Human Resources and Social Security (人力資源社會保障部) and the Ministry of Industry and Information Technology (工業和信息化部) in April 2025. He also held a B-level Tianfu Talent Card (天府英才卡B卡) of Sichuan Province from May 2020 to April 2021 and was commended as an individual advanced in the China Democratic National Construction Association's fight against COVID-19 (民建抗擊新冠肺炎疫情先進個人).

Dr. David Guowei WANG (formerly known as Wang Guowei (王國瑋)), aged 64, is a non-executive Director of our Company. Dr. Wang has joined the Group and served as a Director of our Company since May 2020 and was re-designated as our non-executive Director in September 2025.

Dr. Wang has around 20 years of experience in the medical industry. Dr. Wang is a partner and senior managing director of OrbiMed Advisors LLC, an investment fund with a focus on the healthcare industry, where he has worked since August 2011, and has served as a director of OrbiMed Advisors III Limited since February 2017. Dr. Wang served as the managing director at WI Harper Group from April 2006 to July 2011. From March 2010 to July 2012, he served on the board of directors of Edan Instruments, Inc. (深圳市理邦精密儀器股份有限公司) (a company listed on the ChiNext Board of the Shenzhen Stock Exchange, stock code: 300206), a provider of advanced electronic medical equipment, where he also served on both the audit committee and strategic committee. He was a director of Suzhou Medical System Technology Co., Ltd. (蘇州麥迪斯頓醫療科技股份有限公司) (a company listed on the Shanghai Stock Exchange, stock code: 603990) from October 2012 to May 2019, a non-executive director of EC Healthcare (醫思健康) (formerly known as Union Medical Healthcare Limited (香港醫思醫療集團有限公司)) (a company listed on the Stock Exchange, stock code: 2138) from August 2018 to April 2020, a director of Amoy Diagnostics Co., Ltd. (廈門艾德生物醫藥科技股份有限公司) (a company listed on the ChiNext Board of the Shenzhen Stock Exchange, stock code: 300685) from June 2015 to August 2021 and a director of Gracell Biotechnologies Inc., a company previously listed on NASDAQ Global Market (previous stock code: GRCL), which was delisted in February 2024 following its acquisition by AstraZeneca, from March 2020 to February 2024. Currently, he holds positions as directors in numerous listed companies, including as (i) a director of SHANGHAI UPPER BIO-TECH PHARMA CO., LTD. (上海奧普生物醫藥股份有限公司) (a company listed on the National Equities Exchange and Quotations, stock code: 873758) since January 2016, (ii) a non-executive director of AK Medical Holdings Limited (愛康醫療控股有限公司) (a company listed on the Stock Exchange, stock code: 1789) since February 2016, (iii) a director of Sichuan Biokin Pharmaceutical Co., Ltd (四川百利天恒藥業股份有限公司) (a company listed on the STAR Market of Shanghai Stock Exchange, stock code: 688506) since September 2017, (iv) a non-executive director of

Gaush Meditech Ltd (高視醫療科技有限公司) (a company listed on the Stock Exchange, stock code: 2407) since December 2017, and (v) a non-executive director of Laekna Inc. (來凱醫藥有限公司) (a company listed on the Stock Exchange, stock code: 2105) since July 2019.

Dr. Wang obtained his bachelor's degree majoring in medicine from Beijing Medical University (北京醫科大學) (currently known as Peking University Health Science Center (北京大學醫學部)) in Beijing, the PRC in July 1986 and a Doctor of Philosophy degree majoring in developmental biology from California Institute of Technology in the United States in June 1995.

Mr. HU Huanrui (胡煥瑞), aged 57, is a non-executive Director of our Company. Mr. Hu has joined the Group and served as a non-executive Director in September 2025.

Mr. Hu has served as a partner at Shanghai Yimei Capital Management L.P. (上海熠美私募基金管理合夥企業(有限合夥)) since October 2010.

Mr. Hu obtained his bachelor's degree majoring in physics from Peking University in Beijing, the PRC in July 1992, and his master in science from Columbia University in the United States in February 1997.

Independent Non-executive Directors

Dr. SUN Xiaobo (孫曉波), aged 67, is an independent non-executive Director of our Company.

Dr. Sun has over 30 years of experience in pharmaceutics industry. Dr. Sun has worked at the Chinese Academy of Medical Sciences (中國醫學科學院) as a master's supervisor since May 2008. From October 2012 to February 2022, he served as the legal representative and the director of the Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences (中國醫學科學院藥用植物研究所). Dr. Sun concurrently holds several academic positions, including a member of the First Committee of the Branch of Chinese Medicinal Resources of the China Association of Chinese Medicine (中華中醫藥學會中藥資源學分會第一屆委員會) from October 2015 to October 2019, the specially-appointed vice president (特聘副會長) of the China Association of Chinese Medicine (中華中醫藥學會) since 2020, and the specially-appointed vice president of the China Association of Traditional Chinese Medicine (中國中藥協會) since 2019.

Dr. Sun has received numerous awards for his contributions in pharmaceutics, including (i) the Second Prize of National Science and Technology Progress Award (國家科學技術進步獎二等獎) granted by the State Council of the PRC in January 2018, (ii) the First Prize of Science and Technology Award (科學技術一等獎) of Chinese Association of Integrative Medicine (中國中西醫結合學會) in November 2024, (iii) the National Award for Excellence in Innovation (全國創新爭先獎) granted by China Association for Science and Technology (中國科學技術協會) in May 2023, (iv) the Special Contribution on Innovative Medicine Award of China Pharmaceutical Development Award (中國藥學發展獎創新藥物特別貢獻獎) granted by the Chinese Pharmaceutical Development Award Working Committee (中國藥學發展獎獎勵工作委員會) in December 2023, and (v) the National May 1st Labor Medal (全國五一勞動獎章) granted by the All-China Federation of Trade Unions (中華全國總工會) in April 2022.

Dr. Sun obtained his bachelor's degree of medicine majoring in pharmaceutical sciences from Medical College of Yanbian (延邊醫學院) in Jilin Province, the PRC in July 1982. He obtained his doctoral degree majoring in crop cultivation and farming from Jilin Agricultural University (吉林農業大學) in Jilin Province, the PRC in June 2004. Dr. Sun was qualified as a chief pharmacist (主任藥師) by Personnel Department of Jilin Province (吉林省人事廳) in January 1994, and was qualified as a doctoral supervisor at the Chinese Academy of Medical Sciences (中國醫學科學院) in May 2009.

Mr. LAU King Pak (劉勁柏), aged 54, is an independent non-executive Director of our Company.

Mr. Lau has over 25 years of experience in the accounting and auditing industry. Mr. Lau served in KPMG Hong Kong from August 1995 to January 1997, with his last position as an accountant. Then he served in the Beijing office of Ernst & Young from September 2000 to April 2011, with his last position as a partner. Mr. Lau later joined Deloitte Touche Tohmatsu and served as a partner from April 2011 to January 2021. He was the managing director of MC CPA Limited, a certified public accountant firm in Hong Kong from January 2022 to November 2022. Mr. Lau served as a non-executive director of DreamEast Group Limited (夢東方集團有限公司) (a company listed on the Stock Exchange, stock code: 593, "**DreamEast**") from June 2022 to June 2023. On 11 March 2024, DreamEast was ordered to be wound up by the High Court of Hong Kong and the Official Receiver by virtue of her office becomes the provisional liquidator of DreamEast. Trading of its shares has been suspended with effect from 11 March 2024. Mr. Lau has confirmed that there was no wrongful act on his part leading to the order of winding up and suspension of trading of shares of DreamEast and such incident has no impact to his ability to discharge the director's duty in the Company.

He had also been an independent non-executive director of China Maple Leaf Educational Systems Limited (中國楓葉教育集團有限公司) (a company listed on the Stock Exchange, stock code: 1317) from February 2023 to February 2024, and has been re-designated as an executive director and co-chief financial officer of China Maple Leaf Educational Systems Limited with effect from 1 March 2024.

Mr. Lau obtained his bachelor's degree of business administration in accounting from the Hong Kong University of Science & Technology (香港科技大學) in Hong Kong in November 1995. Mr. Lau is a practicing member of Hong Kong Institute of Certified Public Accountants and holds a Certified Public Accountant (Practising) certificate issued by the Accounting and Financial Reporting Council in Hong Kong.

Mr. CAI Longjun (蔡龍軍), aged 42, is an independent non-executive Director of our Company.

Mr. Cai has over 10 years of experience in AI industry. Mr. Cai has served as a software developer at IBM (China) Investment Company Limited, a subsidiary of International Business Machines Corporation (a company listed on the New York Stock Exchange, stock code: IBM) from July 2008 to October 2012. He then served as a scientist in Beijing Qiyi Century Technology Ltd. (北京奇藝世紀科技有限公司) from September 2012 to October 2016. From February 2017 to January 2022, he served as a senior algorithm expert at Youku Internet Technology (Beijing) Co., Ltd. (優酷網絡技術(北京)有限公司). Since January 2022, Mr. Cai has served as the chief technology officer and chief operation officer of BrainAurora Medical Technology Limited (腦動極光醫療科技有限公司) (a company listed on the Stock Exchange, stock code: 6681), where he also serves as the chief executive officer since June 2025.

Mr. Cai obtained his bachelor's degree majoring in e-commerce and his master's degree majoring in transportation planning and management from Beijing Jiaotong University (北京交通大學) in Beijing, the PRC in July 2006 and July 2008, respectively. He has been pursuing his doctoral degree majoring in electronic information at Tsinghua University (清華大學) in Beijing, the PRC since September 2024.

Each of our Directors has confirmed that he or she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules in September 2025, and (ii) understands his or her obligations as a director of a listed issuer under the Listing Rules.

Save as disclosed in this document, (i) none of our Directors had any other relationship with any Directors, senior management or Controlling Shareholders of our Company as of the Latest Practicable Date; (ii) none of our Directors held any directorship in any other listed companies in the three years immediately prior to the date of this document; and (iii) as of the Latest Practicable Date, none of our Directors (other than our independent non-executive Directors) had interests in business, which competes or is likely to compete, either directly or indirectly with our business, which would require disclosure under Rule 8.10 of the Listing Rules.

Save as disclosed herein, to the best knowledge, information and belief of our Directors having made all reasonable enquiries, there was no other matter with respect to the appointment of our Directors that needs to be brought to the attention of the Shareholders and there was no information relating to our Directors that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules as of the Latest Practicable Date.

SENIOR MANAGEMENT

The following table sets forth certain information of the senior management of the Group:

Name	Age	Position	Principal roles and responsibilities	Date of joining our Group	Date of appointment as Senior Management	Relationship with other Directors and senior management
Ms. GENG Jie	39	Chairwoman of the Board and executive Director	Responsible for overall development strategies, major decisions and overall management of the Group	July 1, 2019	July 17, 2019	Spouse of Mr. XUE Yuan; sister of Mr. GENG Yuefei
Mr. SU Yazhou (蘇亞洲)	40	Executive Director and chief executive officer	Responsible for the overall operations and management and participating in formulating material plans of the Company	December 5, 2019	February 10, 2023	None
Mr. XUE Yuan (薛源)	43	Executive Director and chief technology officer	Responsible for overseeing information technology and supply chain operations and participating in formulating material plans of the Company	December 1, 2019	October 31, 2023	Spouse of Ms. GENG Jie

Name	Age	Position	Principal roles and responsibilities	Date of joining our Group	Date of appointment as Senior Management	Relationship with other Directors and senior management
Dr. XUE Chong (薛翀)	45	Chief scientist	Responsible for leading medical AI related activities	April 7, 2026	April 7, 2026	None
Mr. YANG Ning (楊寧).	44	Chief financial officer, secretary of the Board and company secretary	Responsible for overseeing the capital markets operations, financial management and corporate governance of the Company	July 29, 2024	July 29, 2024	None

For the biographical details of Ms. Geng Jie, Mr. Su Yazhou, and Mr. Xue Yuan, please refer to "Executive Directors" in this section. Biographical details of other members of the senior management are as follows:

Dr. XUE Chong (薛翀), aged 45, has been our chief scientist since April 2026.

Dr. Xue has over 20 years of experience in the medical industry. From September 2010 to October 2016, Dr. Xue served in the department of urology at The Second Affiliated Hospital, Zhejiang University School of Medicine (浙江大學醫學院附屬第二醫院) as an attending physician. From April 2013 to March 2014, he conducted postdoctoral research at Johns Hopkins University School of Medicine with a research focus on AI algorithm-guided robotic surgery, where his research on medical robotics based on intelligent medical imaging algorithms was recognised as one of the Top 10 Abstracts by the American Urological Engineering Association in 2014. Then he founded Hangzhou Trizen Medical Technology Co., Ltd. (杭州全診醫學科技有限公司), and has served as the chairman of the board and general manager since January 2016. Dr. Xue also holds a number of social positions, including serving as the vice president of the First "AI + Healthcare" Innovation Committee of Zhejiang Social Healthcare Providers Association (浙江省社會辦醫協會第一屆"AI+醫療"創新分會) since May 2025, and the vice director member of the Special Committee on Supervision and Services for Socially-run Medical Institutions of the Zhejiang Health Supervision Association (浙江省衛生監督協會社會辦醫監督與服務專業委員會) since August 2025.

Dr. Xue obtained his bachelor's degree majoring in clinical medicine from The Second Military Medical University (第二軍醫大學) (currently known as Naval Medical University (中國人民解放軍海軍軍醫大學)) in Shanghai, the PRC in June 2003. He obtained his doctoral degree majoring in surgery from Peking Union Medical College, Chinese Academy of Medical Sciences (中國醫學科學院北京協和醫學院) in July 2010. Dr. Xue has held the Physician Qualification Certificate (醫師資格證書) issued by the Ministry of Health of the People's Republic of China (中華人民共和國衛生部) since December 2004. He has been holding the Senior Professional Technical Certificate of Artificial Intelligence Algorithm Engineer (人工智能算法工程師(高級)職業技術證書) issued by the Ministry of Industry and Information Technology (工業和信息化部) since January 2026.

Mr. YANG Ning (楊寧), aged 44, has been our chief financial officer and secretary of the Board since July 2024 and our company secretary since September 2025.

Mr. Yang has over 18 years of experience in accounting and finance. Mr. Yang worked as an auditor at Ernst & Young Hua Ming LLP from December 2006 to December 2010, with his last position as a senior auditor. From December 2010 to April 2017, he worked at Deloitte Touche Tohmatsu Certified Public Accountants LLP, Beijing Branch, with his last position as a senior manager at the audit and assurance department. From February 2016 to February 2017, he was assigned by Deloitte Touche Tohmatsu to act as an advisory assistant at China Securities Regulatory Commission, where he was responsible for the analysis and review of annual reports, improving the information disclosure regime, and providing professional support for the regulation of the accounting profession. From April 2017 to March 2019, Mr. Yang was the secretary of the board of directors of Puritek Co. Ltd (博瑞德環境集團股份有限公司) ("**Puritek**"), a PRC company specialising in technology research and development in the field of sewage treatment and environment protection, and he has served as a director of Puritek since April 2017. Mr. Yang served in Immunotech Biopharm Ltd (永泰生物製藥有限公司) (a company listed on the Stock Exchange, stock code: 6978) as the chief financial officer from April 2019 to July 2024, and as the company secretary from August 2021 to July 2024. He has served as an independent director of Shandong Hongqiao Aluminum Industry Holding Company Limited (山東宏橋鋁業控股股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 002379) since January 2026.

Mr. Yang obtained his bachelor of arts degree majoring in Japanese and double bachelor's degree in economics from Peking University (北京大學) in Beijing, the PRC in July 2003. He obtained his master's degree of commerce from The University of Queensland, Australia in December 2005. He has been a member of CPA Australia since March 2010. He has also been a member of the Chinese Institute of Certified Public Accountants since June 2016, and has become a non-practising member since May 2017.

COMPANY SECRETARY

Mr. YANG Ning (楊寧) is the chief financial officer, secretary of the Board and company secretary of our Company. For the biographical details of Mr. Yang, see "— Senior Management."

BOARD COMMITTEES

Our Company has established three Board Committees in accordance with the relevant PRC laws and regulations, the Articles and the corporate governance practice under the Listing Rules, namely the Audit Committee, the Remuneration and Appraisal Committee and the Nomination Committee.

Audit Committee

We have established an audit committee (the "**Audit Committee**") in compliance with the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The Audit Committee consists of Mr. LAU King Pak, Dr. SUN Xiaobo and Mr. CAI Longjun. Mr. LAU King Pak holds the appropriate professional qualification as required under Rules 3.10(2) and 3.21 of the Listing Rules and currently serves as the chairperson of the Audit Committee. The primary duties of the Audit Committee are as follows: (i) to review significant financial policies of the Company and their implementation, and supervise the financial activities of the Company; (ii) to review the financial information and relevant disclosures of the Company; (iii) to supervise and evaluate the risk management and internal control of the Company; (iv) to supervise and evaluate the work of internal audit of the Company and report to the Board; (v) to propose the appointment or dismissal of an external accounting firm; (vi) to facilitate communications and monitor the relationship between the internal audit department and the external accounting firm; (vii) to monitor the non-compliance of the Company in respect of the financial reports and the risk management and internal control; and (viii) other matters required by laws, regulations, regulatory documents, the rules of the securities regulatory authority of the place where the Shares of the Company are listed and the requirements of the Memorandum and the Articles of Association, and as authorized by the Board.

Remuneration and Appraisal Committee

We have established a remuneration and appraisal committee (the "**Remuneration and Appraisal Committee**") in compliance with the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The Remuneration and Appraisal Committee consists of Dr. SUN Xiaobo, Mr. LAU King Pak and Mr. CAI Longjun. Dr. SUN Xiaobo currently serves as the chairperson of the Remuneration and Appraisal Committee. The primary duties of the Remuneration and Appraisal Committee are as follows: (i) to organize and formulate the remuneration policy and plan of Directors and senior management and submit to the Board for approval; and (ii) other matters required by laws, regulations, regulatory documents, the rules of the securities regulatory authority of the place where the Shares of the Company are listed and the requirements of the Memorandum and the Articles of Association, and as authorized by the Board.

Nomination Committee

We have established a nomination committee (the "**Nomination Committee**") in compliance with the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The Nomination Committee consists of Ms. GENG Jie, Dr. SUN Xiaobo and Mr. LAU King Pak. Ms. GENG Jie currently serves as the chairperson of the Nomination Committee. The primary duties of the Nomination Committee are as follows: (i) to formulate procedures and standards for the election of Directors and senior management and make recommendations to the Board on the proposed procedures and standards; (ii) to make recommendations to the Board on the nomination of candidates for Directors, Presidents and secretary of the Board; (iii) to preliminarily examine the eligibility of candidates for Directors and senior management; (iv) to make recommendations to the Board on the nomination of candidates for chairmen and members of the Board committees; and (v) other matters required by laws, regulations, regulatory documents, the rules of the securities regulatory authority of the place where the Shares of the Company are listed and the requirements of the Memorandum and the Articles of Association, and as authorized by the Board.

BOARD DIVERSITY POLICY

Pursuant to our board diversity policy, selection of Board candidates will be based on a range of diversity perspectives, including but not limited to gender, age, cultural and educational background, industry experience, technical capabilities, professional qualifications and skills, knowledge, length of service and other related factors. We will also consider our own business model and special needs. The ultimate selection of Director candidates will be based on merits of the candidates and contribution that the candidates will bring to our Board.

Our Board currently consists of one female Director and eight male Directors with a balanced mix of knowledge and skills, including but not limited to overall management and strategic development, finance, accounting and risk management. The Company is of the view that the Board satisfies our board diversity policy.

Our Nomination Committee is responsible for the implementation of our board diversity policy. Upon completion of the [**REDACTED**], our Nomination Committee will review our board diversity policy from time to time to ensure its continued effectiveness and we will disclose the implementation of our board diversity policy in our corporate governance report on an annual basis.

REMUNERATION OF DIRECTORS AND SENIOR MANAGEMENT

The Directors and senior management members receive remuneration in the forms of salaries, allowances and benefits in kind, performance related bonuses, share-based payment expenses, and pension scheme contributions.

The aggregate amount of remuneration (including salaries, allowances and benefits in kind, performance related bonuses, share-based payment expenses, and pension scheme contributions) paid to our Directors for the three years ended December 31, 2023, 2024 and 2025 were approximately RMB1.57 million, RMB3.58 million and RMB3.67 million, respectively.

Under the arrangements currently in force, the aggregate amount of remuneration (including any discretionary bonus which may be paid) payable by our Group to our Directors for the financial year ending December 31, 2026 is expected to be approximately RMB4.84 million.

The aggregate amount of salaries, allowances and benefits in kind, performance related bonuses, share-based payment expenses, and pension scheme contributions paid to the five highest-paid individuals of our Group for the three years ended December 31, 2023, 2024 and 2025 were approximately RMB3.65 million, RMB5.66 million and RMB5.78 million, respectively.

During the Track Record Period, there was no remuneration paid or payable by our Company to our Directors or the five highest-paid individuals as an inducement to join or upon joining our Company. During the Track Record Period, there was no compensation paid or payable by our Company to our Directors, former Directors or the five highest-paid individuals for the loss of any office in connection with the management of the affairs of any subsidiary of our Company.

During the Track Record Period, none of our Directors has waived or agreed to waive any remuneration or benefits in kind for the past three years. Save as disclosed above, there was no other payments paid or payable by our Company or any of our subsidiaries to our Directors or the five highest-paid individuals during the Track Record Period.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

We are committed to achieving high standards of corporate governance which are crucial to our development and safeguard the interests of our Shareholders. To accomplish this, we expect to comply with the corporate governance requirements under the Corporate Governance Code and Corporate Governance Report as set out in Appendix C1 to the Listing Rules after the [**REDACTED**].

PRE-[REDACTED] SHARE INCENTIVE SCHEME

For more information, please refer to "Appendix VI — Statutory and General Information — Further Information about Our Directors, Management and Substantial Shareholders — Pre-[**REDACTED**] Share Incentive Scheme."

COMPLIANCE ADVISOR

We have appointed Alliance Capital Partners Limited as our Compliance Advisor upon the [**REDACTED**] pursuant to Rule 3A.19 of the Listing Rules. The material terms of the compliance advisor's agreement are as follows:

(i) Alliance Capital Partners Limited shall act as our Compliance Advisor for the purpose of Rule 3A.19 of the Hong Kong Listing Rules for a period commencing on the [**REDACTED**] and ending on the date on which we comply with Rule 13.46 of the Hong Kong Listing Rules in respect of our financial results for the first full financial year commencing after the [**REDACTED**], or until the agreement is terminated, whichever is earlier;

(ii) the Compliance Advisor will provide us with certain services, including proper guidance and advice as to compliance with the requirements under the Hong Kong Listing Rules and applicable laws, regulations and rules;

(iii) the Compliance Advisor will, as soon as reasonably practicable, inform us of any amendment or supplement to the Hong Kong Listing Rules announced by the Hong Kong Stock Exchange from time to time, and of any amendment or supplement to the applicable laws, regulations and rules in Hong Kong applicable to the Company; and

(iv) the Compliance Advisor will act as an additional channel of communication of the Company with the Hong Kong Stock Exchange.